GEN Exclusives

More »

Feature Articles

More »
Dec 1, 2010 (Vol. 30, No. 21)

Synthetic Bio Not Yet Ready for the Market

Lab-Designed Calls and Pathways Take Genetic and Metabolic Engineering to Next Level

  • In May of this year, the J. Craig Venter Institute (JCVI) announced it had created the first fully synthetic, self-replicating bacterial cell (Mycoplasma nycoides JCVI-syn1.0). While this proof-of-concept demonstration of an “artificial life form”  might raise justifiable fears about the dangers of unregulated or nefarious synthetic biology efforts, in fact the bioindustry has for some time been forging ahead with globally and commercially meaningful applications.

    This fall, JCVI along with Synthetic Genomics (SGI), which was co-founded by Craig Venter and Hamilton Smith, formed a new company named Synthetic Genomics Vaccines.

    The vaccines company has signed a three-year collaboration with Novartis  to create influenza seed (starter-culture) strains for large-scale manufacture of flu vaccines. The intention is to reduce vaccine production time by having a bank of synthetically produced seed viruses; this should accelerate production of flu vaccines for seasonal or pandemic applications instead of relying on  WHO’s more time-lagging distribution of live reference viruses.

    “The rate-limiting step in developing seasonal flu vaccines is the production of pure vaccine seeds specific to flu virus strains that change from year to year,” says Jim Flatt, Ph.D., CTO at SGI. “Synthetically developing vaccine seeds provides the opportunity to significantly reduce the time to develop and produce the seed stock, thereby getting vaccines to market sooner.”

  • Roll-Out to Commercialization

    Dr. Flatt says that SGI, through its supported research at JCVI, has developed a “one-pot, isothermal method to assemble pieces of DNA rapidly and accurately.” SGI is applying the platform to develop cyanobacteria for production of products ranging from biofuels to food and feed ingredients. Scientists at JCVI and SGI are also developing what they describe as a pioneering methodology to transplant whole genomes into recipient cells.

    SGI says its milestones to date follow its predicted trajectory of the commercialization of synthetic biology products.

    “The first products will likely be synthetic genomic tool-based products that facilitate more rapid, cost-effective synthesis and assembly of DNA molecules for both research and commercial purposes. Soon thereafter, we expect to see seasonal flu vaccines, developed from commercialized vaccine seeds,” says Dr. Flatt.

    “Subsequently, one can expect to see engineered microbial biocatalysts and processes designed around commercialized biocatalysts—first in food and feed markets and, later, in agriculture and biofuels. The specific time frames to commercialize products in each of these fields is partially dependent upon receiving regulatory approvals both for products and manufacturing processes, which are unique to each market.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »